Could a stomach drug help fight pancreatic cancer?
NCT ID NCT05827055
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This trial investigates whether adding proglumide, a drug that blocks cholecystokinin receptors, to standard chemotherapy can improve treatment for metastatic pancreatic cancer. About 30 adults with advanced pancreatic cancer will receive either proglumide or a placebo alongside gemcitabine and nab-paclitaxel. The study aims to see if proglumide can safely reduce fibrosis in the tumor environment and potentially improve survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Proglumide
What this could lead to
If successful, this approach could offer a new way to make chemotherapy more effective for people with metastatic pancreatic cancer.
What could go wrong
This is a small, early-phase trial. The drug may not improve outcomes or could add side effects. Results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Lombardi Comprehensive Cancer Center, Georgetown University
Washington D.C., District of Columbia, 20007, United States